NVS - Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

2024-06-05 11:52:26 ET

Summary

• Voyager Therapeutics, Inc. is a biotech company focused on developing gene-based therapies for neurological conditions.
• The company has made progress in its pipeline, including the start of the Phase 1 clinical trial for VY-TAU01, its Alzheimer's disease candidate.
• Voyager's strong revenue-driver partnerships and financial stability make it a "Strong Buy" for long-term investors.

Thesis

Voyager Therapeutics, Inc. ( VYGR ) is a biotechnology company in the clinical stage, which is focused on developing novel therapies, mostly gene-based therapies, for the treatment of conditions that alter the nervous system such as Alzheimer's disease ((AD)), amyotrophic lateral sclerosis ((ALS)), Friedreich's Ataxia, Huntington's disease ((HD)), Parkinson's disease ((PD)), among others.

A few months ago, I took an in-depth look into Voyager's technology, its pipeline and financials based on their FY 2023 10K report. Back then, the share price was standing around $9. Since then, the stock has continued to show high volatility, sliding to around $7.50 and bouncing back to its current $8.51. In my previous article, I rated the stock as a "Buy" based on the strong partnerships with companies such as Novartis AG (NVS), Neurocrine Biosciences, Inc. ( NBIX ) and AstraZeneca PLC (AZN), the great potential of VYGR's TRACER capsids, which can deliver therapeutic molecules to the brain via an intravenous injection, and its strong balance sheet....

For further details see: